Publications by authors named "James B Coutcher"

Claim this Profile
I
Implementing tokenization in clinical research to expand real-world insights.
Chelsea Walters, Crystal S Langlais, Eva E Oakkar, Wilhelmina E Hoogendoorn, James B Coutcher

Front Drug Saf Regul· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A selective aldose reductase inhibitor of a new structural class prevents or reverses early retinal abnormalities in experimental diabetic retinopathy.
Wei Sun, Peter J Oates, James B Coutcher, Chiara Gerhardinger, Mara Lorenzi

Diabetes· October 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A novel series of non-carboxylic acid, non-hydantoin inhibitors of aldose reductase with potent oral activity in diabetic rat models: 6-(5-chloro-3-methylbenzofuran-2-sulfonyl)-2H-pyridazin-3-one and congeners.
Banavara L Mylari, Sandra J Armento, David A Beebe, Edward L Conn, James B Coutcher

J Med Chem· October 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Design and synthesis of a novel family of triazine-based inhibitors of sorbitol dehydrogenase with oral activity: 1-[4-[3R,5S-dimethyl-4-(4-methyl-[1,3,5]triazin-2-yl)-piperazin-1-yl]-[1,3,5]triazin-2-yl]-(R) ethanol.
Banavara L Mylari, Gregory J Withbroe, David A Beebe, Nathaniel S Brackett, Edward L Conn, James B Coutcher

Bioorg Med Chem· September 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A highly selective, non-hydantoin, non-carboxylic acid inhibitor of aldose reductase with potent oral activity in diabetic rat models: 6-(5-chloro-3-methylbenzofuran- 2-sulfonyl)-2-H-pyridazin-3-one.
Banavara L Mylari, Sandra J Armento, David A Beebe, Edward L Conn, James B Coutcher

J Med Chem· June 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A sorbitol dehydrogenase inhibitor of exceptional in vivo potency with a long duration of action: 1-(R)-[4-[4-(4,6-dimethyl[1,3,5]triazin-2-yl)- 2R,6S-dimethylpiperazin-1-yl]pyrimidin-2- yl]ethanol.
Banavara L Mylari, Peter J Oates, William J Zembrowski, David A Beebe, Edward L Conn, James B Coutcher

J Med Chem· September 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
SAR and species/stereo-selective metabolism of the sorbitol dehydrogenase inhibitor, CP-470,711.
Margaret Y Chu-Moyer, William E Ballinger, David A Beebe, James B Coutcher, Wesley W Day

Bioorg Med Chem Lett· June 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Orally-effective, long-acting sorbitol dehydrogenase inhibitors: synthesis, structure-activity relationships, and in vivo evaluations of novel heterocycle-substituted piperazino-pyrimidines.
Margaret Y Chu-Moyer, William E Ballinger, David A Beebe, Richard Berger, James B Coutcher

J Med Chem· January 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis